Clinical Trials Logo

Hepatitis C Relapse clinical trials

View clinical trials related to Hepatitis C Relapse.

Filter by:
  • None
  • Page 1

NCT ID: NCT03145844 Completed - Hepatitis C Clinical Trials

Direct Acting Agents in Hepatitis C Patients

HEPCTURKEY
Start date: April 9, 2017
Phase:
Study type: Observational

This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.

NCT ID: NCT03090035 Completed - Hepatitis C Clinical Trials

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Start date: January 1, 2014
Phase: Phase 3
Study type: Interventional

Objective: Pegulated Interferon α2 plus ribavirin is a treatment of choice in patients with chronic hepatitis C infection. This study was conducted to find out the frequency of different IL-28B (rs12979860) genotypes in patients with chronic hepatitis C (HCV genotype type 2 & 3) infection treated with Pegulated Interferon α2 plus ribavirin and to evaluate the role of IL-28B genotypes in achieving Sustained Virological Response (SVR). Methods: In this non-randomized observational study, ninety eight (98) patients with diagnosis of chronic hepatitis C were included. In all patients, Peg-IFN plus Ribavirin were given in standard doses for 24 weeks. End treatment response, sustained virological response, and relapse rate were the primary endpoints of this study. Analysis of IL28B (rs12979860) polymorphism (CC, CT and TT) was performed by PCR-RFLP protocol.